Aetna expands cancer treatment prior authorization bundles to all Medicaid members by 2027.

Aetna, a CVS Health company, is expanding its prior authorization bundles for all cancer types to eligible Medicaid members starting September 1, 2026, with plans to cover all its business lines by 2027. This initiative simplifies the approval process by combining multiple cancer treatment authorizations into a single request, reducing administrative burdens for providers and speeding patient access to care. The program currently covers states like OK, IL, MD, NJ, VA, FL, KY, and WV, and is expected to expand to Medicare and Commercial members in early 2027. This move aims to help oncologists focus more on patient care and less on paperwork, improving treatment efficiency and patient experience.

CVS Health Corp shares are trading at USD 92.01 on Pluang as of Sep 17, 2026 18:12 WIB, showing a modest 0.32% increase in one day. The company's market cap stands at $117.31 billion, reflecting its significant presence in the health sector. This expansion of oncology prior authorizations aligns with CVS's ongoing efforts to enhance healthcare services and operational efficiency.